GLP-3 retatrutide pipeline triple-agonist explained — how PlexusDx compounded semaglutide and tirzepatide compare in 2026

GLP-3 Retatrutide Explained (2026): Pipeline Triple-Agonist vs PlexusDx GLP-1 Options Available Today | PlexusDx

GLP-3 retatrutide explained: triple-agonist mechanism, Phase 3 TRIUMPH data, dysesthesia signal, FDA timeline, and how PlexusDx’s currently-available compounded semaglutide and tirzepatide protocols compare to the pipeline asset.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →